Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

Phase 2

Completed

Conditions: Chronic Graft Versus Host Disease

Interventions: Drug: bortezomib
Drug: Prednisone

First Posted Date: 2008-12-31

Last Posted Date: 2015-07-22

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 22

Registration Number: NCT00815919

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Calcineurin Free Immunosuppression in Renal Transplant Recipients

Phase 4

Completed

Conditions: Kidney Transplantation
Chronic Kidney Disease

Interventions: Drug: Cyclosporine A
Drug: Sirolimus
Drug: Prednisone
Drug: Mycophenolate mofetil
Procedure: Protocol biopsies

First Posted Date: 2008-12-19

Last Posted Date: 2008-12-19

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 127

Registration Number: NCT00812123

Locations: 🇨🇭
University Hospital Basel, Clinic for Transplantation Immunology and Nephrology, Basel, Switzerland

Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC)

Phase 2

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Taxotere
Drug: Prednisone

First Posted Date: 2008-12-18

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00811031

R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: Non-Hodgkin's Lymphoma

Interventions: Biological: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: High-dose cyclophosphamide
Procedure: PET scan

First Posted Date: 2008-12-17

Last Posted Date: 2018-09-25

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 27

Registration Number: NCT00809341

Locations: 🇺🇸
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Conditions: Multiple Myeloma

First Posted Date: 2008-12-01

Last Posted Date: 2015-12-02

Lead Sponsor: Janssen-Ortho Inc., Canada

Registration Number: NCT00799539

Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia
Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Adult L1 Acute Lymphoblastic Leukemia
Adult L2 Acute Lymphoblastic Leukemia
Adult T Acute Lymphoblastic Leukemia
Recurrent Adult Acute Lymphoblastic Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Dasatinib
Drug: Dexamethasone
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Biological: Filgrastim
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Methotrexate
Drug: Methylprednisolone
Procedure: Peripheral Blood Stem Cell Transplantation
Drug: Prednisone
Drug: Sirolimus
Drug: Tacrolimus
Radiation: Total-Body Irradiation
Drug: Vincristine Sulfate

First Posted Date: 2008-11-18

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 97

Registration Number: NCT00792948

Locations: 🇺🇸
Cancer Center of Kansas-Kingman, Kingman, Kansas, United States
🇺🇸
Lawrence Memorial Hospital, Lawrence, Kansas, United States
🇺🇸
Southwest Medical Center, Liberal, Kansas, United States

and more 154 locations

TNF-alpha Antagonists for AECOPD: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial

Phase 2

Completed

Conditions: COPD Exacerbation

Interventions: Drug: Etanercept
Drug: Prednisone
Drug: levofloxacin

First Posted Date: 2008-11-13

Last Posted Date: 2016-04-11

Lead Sponsor: Ottawa Hospital Research Institute

Target Recruit Count: 81

Registration Number: NCT00789997

SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Lymphoma

Interventions: Drug: Zolinza (vorinostat)
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2008-11-07

Last Posted Date: 2014-09-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00787527

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

Phase 2

Completed

Conditions: Lupus Nephritis
Lupus Erythematosus, Systemic

Interventions: Drug: cyclophosphamide
Drug: abatacept
Drug: azathioprine
Drug: abatacept placebo
Drug: prednisone
Drug: azathioprine placebo

First Posted Date: 2008-10-17

Last Posted Date: 2016-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 137

Registration Number: NCT00774852

Locations: 🇺🇸
Feinstein Institute, Manhasset, New York, United States
🇺🇸
UT Southwestern, Dallas, Texas, United States
🇺🇸
University of Alabama, Birmingham, Birmingham, Alabama, United States

and more 20 locations

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

Not Applicable

Terminated

Conditions: Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma

Interventions: Drug: Rituximab
Drug: Bortezomib
Drug: Cyclophosphamide
Drug: Prednisone

First Posted Date: 2008-10-15

Last Posted Date: 2017-12-11

Lead Sponsor: University of Miami

Target Recruit Count: 3

Registration Number: NCT00772668

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy